Hepatitis B Community
improved hbsag loss to 29.61% by pegintf+nucs 120weeks
About This Community:

This forum is an un-mediated, patient-to-patient forum for questions and support regarding Hepatitis B. Topics in this forum include but are not limited to, Causes, Diagnosis, Family and Relationships, Living With Hepatitis B, Research Updates, Treatment, Success Stories, Support, Symptoms.

Font Size:
A
A
A
Background:
Blank
Blank
Blank
Blank Blank

improved hbsag loss to 29.61% by pegintf+nucs 120weeks

http://www.natap.org/2013/EASL/EASL_70.htm

Program Abstract

Aims: To investigate the improved HBsAgresponse in chronic hepatitis B (CHB) patients treated with prolonged peginterferon α-2a combined with nucleos(t)ide analogue.

Methods: One hundred and fifty-two CHB patients treated with peginterferon α-2a plus nucleos(t)ide analogue from Jan 2007 to Sep 2012 were retrospectively investigated. The mean treatment duration was 79 weeks (range 24-120 weeks). Serum HBsAglevels at baseline, week 12, 24, 36, 48, 72, 96 and 120 of treatment were detected

Results: The cumulative HBsAgloss rates of patients treated at 48-week, 96-week and 120-week with peginterferon α-2a plus nucleos(t)ide analogue were 8.55% (13/152), 26.97% (41/152) and 29.61% (45/152), respectively. The time to HBsAgloss was 74.93±27.21 weeks. Most HBsAgloss occurred during week 49-96. The HBsAglevel at week 12 of treatment in 45 patients who obtained HBsAgloss was 1.91±1.27log10IU/mL, which was significantly lower than baseline (3.22±0.82log10IU/mL) (t=5.759, P< 0.01). However, the HBsAglevel at baseline in 107 patients who did not obtain HBsAgloss was 3.57±0.96 log10 IU/mL and HBsAglevels reduction at week 12, 24, 48, 96 and 120 were 0.24±0.38, 0.45±0.60, 0.83±0.84, 1.29±1.05 and 1.66±1.66 log10IU/ml, respectively (Figure 1). As expected, the HBsAglevel at week 12 of treatment was not significantly different from that at baseline in this group of patients (t=1.529, P=0.128), while that at week 96 was significantly decreased compared with week 48 (t=2.166, P=0.033).

Conclusion: Prolonged peginterferon α-2a combined with nucleos(t)ide analogue treatment could increase the cumulative HBsAgloss rate. In patients who do not obtain HBsAgloss, prolonged therapy could reduce the HBsAglevel and improve the anti-viral response. The reduction of HBsAglevel of week 12 from baseline could be a predictor of HBsAgclearance
8 Comments Post a Comment
Blank
Avatar_m_tn
very very important that the most hbsag decrease or response to pegintf+nucs was on 49-96weeks

this means the routine treatment of 48weeks is wrong, another study also showed that the max effect on immune system by pegintf is after 48weeks
Blank
Avatar_m_tn
another consideration: sequential treatment response is still the best even at 48weeks combo add on

pgintf+nucs 120weeks 29.61% hbsag loss
nucs long term 3-7years and then pegintf add on 48weeks 50% hbsag loss
Blank
Avatar_m_tn
I was told NO many times to my requests for this type of treatment. They are butchering us here. :(  only damn nucs is all they prescribe.

Listen to this what I am told. That they dont give interferon to people with undetectable DNA apparently according to US standards that insurance companies have in place for them.
Blank
Avatar_m_tn
I sure would like to see gamma interferon results. In comparison to this.
Blank
1024307_tn?1292002086
nucs long term 3-7years and then pegintf add on 48weeks 50% hbsag loss



This is something!
Is the 50% HBsAg loss in both cases: HBeAg positive and negative?
50% -that's high.
Blank
Avatar_m_tn

yes
Blank
Avatar_m_tn
i mean after 3-7years on nucs you get hbeag negative anyway....
Blank
Avatar_m_tn
and the point is not hbeag, it doesn t matter, it is hbsag decline that matters
Blank
Post a Comment
To
Blank
Weight Tracker
Weight Tracker
Start Tracking Now
Hepatitis B Community Resources
RSS Expert Activity
469720_tn?1388149949
Blank
Abdominal Aortic Aneurysm-treatable... Blank
Oct 04 by Lee Kirksey, MDBlank
242532_tn?1269553979
Blank
The 3 Essentials to Ending Emotiona...
Sep 18 by Roger Gould, M.D.Blank
242532_tn?1269553979
Blank
Control Emotional Eating with this ...
Sep 04 by Roger Gould, M.D.Blank
Top Hepatitis Answerers
Avatar_m_tn
Blank
stef2011
Italy
Avatar_m_tn
Blank
StephenCastlecrag
Australia
Avatar_m_tn
Blank
veteranB
CA
Avatar_m_tn
Blank
mike9111
MI
Avatar_m_tn
Blank
SafiSifa
Izmir, Turkey
7951432_tn?1400922437
Blank
flyinsky
paris, France